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The Effect of a Connexin43-Based Peptide on the
Healing of Chronic Venous Leg Ulcers: A Multicenter,
Randomized Trial
Gautam S. Ghatnekar1, Christina L. Grek1, David G. Armstrong2, Sanjay C. Desai3 and Robert G. Gourdie4,5,6
The gap junction protein, connexin43 (Cx43), has critical roles in the inflammatory, edematous, and fibrotic
processes following dermal injury and during wound healing, and is abnormally upregulated at the epidermal
wound margins of venous leg ulcers (VLUs). Targeting Cx43 with ACT1, a peptide mimetic of the carboxyl-terminus
of Cx43, accelerates fibroblast migration and proliferation, and wound reepithelialization. In a prospective,
multicenter clinical trial conducted in India, adults with chronic VLUs were randomized to treatment with an ACT1
gel formulation plus conventional standard-of-care (SOC) protocols, involving maintaining wound moisture and
four-layer compression bandage therapy, or SOC protocols alone. The primary end point was mean percent ulcer
reepithelialization from baseline to 12 weeks. A significantly greater reduction in mean percent ulcer area from
baseline to 12 weeks was associated with the incorporation of ACT1 therapy (79% (SD 50.4)) as compared with
compression bandage therapy alone (36% (SD 179.8); P¼ 0.02). Evaluation of secondary efficacy end points
indicated a reduced median time to 50 and 100% ulcer reepithelialization for ACT1-treated ulcers. Incorporation of
ACT1 in SOC protocols may represent a well-tolerated, highly effective therapeutic strategy that expedites chronic
venous ulcer healing by treating the underlying ulcer pathophysiology through Cx43-mediated pathways.
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INTRODUCTION
Venous leg ulcers (VLUs) develop as a result of chronic
venous insufficiency, leading to venous hypertension and
small vessel damage. Persistent inflammation within the
extracellular matrix of the wound bed and the detrimental
upregulation of connexins contribute to dysfunction of
wound fibroblasts and keratinocytes and the underlying
pathophysiology associated with an impaired wound-healing
response in chronic VLUs (Brandner et al., 2004;
Charles et al., 2008; Mendoza-Naranjo et al., 2012; Kim
et al., 2014). In industrialized countries, VLUs affect B3% of
people over 65 years of age (Fletcher et al., 1997; Bergan
et al., 2006). Given that therapeutic intervention extending
beyond 1 year is common, and recurrence rates are B60–
70%, VLUs present a substantial economic and societal
burden on the individual, family, and health-care system (de
Araujo et al., 2003; Abbade and Lastoria, 2005; O’Meara
et al., 2012).
Conventional treatment protocols involving infection con-
trol, nonadherent wound dressing, and limb compression
remain the cornerstone of conservative treatment, healing
between 30 and 75% of VLUs (O’Meara et al., 2009). The
Wound Healing Society suggests incorporation of adjunctive
therapies in the treatment of VLUs that remain unresponsive to
standard-of-care (SOC) treatment beyond 4 weeks (Tang et al.,
2012). Randomized controlled trials demonstrate the potential
of advanced wound care matrices, such as Apligraf
(Organogenesis Inc., Canton, MA). However, such living
skin equivalents remain cumbersome, time-consuming and
expensive, offer modest improvement over SOC, and may not
address the underlying pathophysiology of chronic ulcers
(Falanga et al., 1998; Hankin et al., 2012).
Gap junction (GJ) proteins have critical roles in the
pathogenesis of chronic wounds, and targeting GJ signaling
offers therapeutic opportunity (Qiu et al., 2003; Gourdie et al.,
2006; Ghatnekar et al., 2009; Churko et al., 2012; Marquez-
Rosado et al., 2012; Mendoza-Naranjo et al., 2012; Wright
et al., 2013; Grek et al., 2014). Connexins are the channel-
forming component of GJs that directly couple the cytoplasm
between cells, permitting the exchange of small molecules
(o1000 Da) and facilitating electrical propagation in excitable
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tissues. Connexin43 (Cx43) has critical roles in the regulation
of inflammatory, edematous, and fibrotic processes following
tissue injury and during healing, and is abnormally
upregulated at the epidermal wound margins of chronic
VLUs (Brandner et al., 2004; Mendoza-Naranjo et al., 2012).
ACT1 is a 25 amino acid synthetic peptide containing the
carboxy-terminal PDZ binding domain of Cx43 that directly
interacts with Cx43 binding partners, thus offering specific and
reversible modulation of GJ communication. When applied
topically on rodent and porcine skin wounds, ACT1 accel-
erates the wound closure rate, reduces inflammatory neutro-
phil infiltration, and reduces scar tissue formation (Gourdie
et al., 2006; Rhett et al., 2008; Ghatnekar et al., 2009). ACT1’s
mechanism of action with regard to tissue regeneration and the
dampening of inflammatory responses is independent of Cx43
expression and is linked to mediated increases in the size of GJ
channel aggregates and the sequestration of hemichannels
from the perinexal region surrounding GJs (Hunter et al., 2005;
Rhett et al., 2011). This study evaluated the efficacy and safety
of ACT1 in accelerating the healing of chronic VLUs when
incorporated into conventional treatment protocols.
RESULTS
Between 5 October 2011 and 10 May 2012, 101 patients
were screened and a total of 92 patients were randomly
assigned 1:1 to a treatment protocol involving ACT1 and
conventional SOC protocols involving the maintenance of a
moist wound environment and the application of compression
bandage therapy or a control treatment of conventional
therapy alone (Figure 1). Randomized groups showed similar
baseline patient demographics in terms of mean age, race,
mean weight, mean body mass index, ankle blood pressure,
baseline mean ulcer area, and ulcer location (Table 1). At
study outset, the participant population had an average ulcer
size of 3.5 cm2 lasting about 17 months.
Of the 92 participants who were assigned to randomization,
14 withdrew consent during the course of the study, 3 were
lost to follow-up, 4 were determined to be in noncompliance
post-facto, and 1 participant died as a result of myocardial
infarction unrelated to intervention, resulting in a total of 70
participants who completed the study. The final analysis
sample sizes consisted of an intent-to-treat (ITT) participant
population (n¼ 92) and a per protocol (PP) participant
population (n¼ 68) made up of participants lacking any major
protocol deviation and present for all ulcer evaluations
(Figure 1). ITT analyses avoid bias associated with the
nonrandom loss of participants and included all participants
with a baseline visit. The PP population excluded participants
who had died, had withdrawn consent, were noncompliant to
the protocol, or had major protocol violations such as missed
visits/treatments and lack of wound evaluation data. Of note,
the number of missing observations was relatively high but
was similar in the control and treatment groups. Selection of
the PP population was made according to the ICH-GCP
guidelines, with complete information on post-randomization
exclusion provided to avoid bias.
Primary and secondary ulcer healing outcomes
Preliminary assessment for normality confirmed a non-normal
distribution of data (Po0.001), supporting the application of
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Figure 1. CONSORT flow diagram of participants. ITT, intent-to-treat; PP, per protocol; SOC, standard of care.
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nonparametric statistical analyses. In both ITT and PP popula-
tions, mean percent reduction in ulcer area and incidence of
100% ulcer reepithelialization at week 12 were significantly
greater in the treatment group incorporating ACT1 as com-
pared with the control group receiving conventional therapy
alone (Table 2). ACT1 application was associated with a
significantly greater reduction in mean percent ulcer area from
baseline to 12 weeks (ITT: 79% (SD 50.4); PP: 79% (SD 51.1))
compared with compression bandage therapy alone (ITT: 36%
(SD 179.8), P¼ 0.024; PP: 29% (SD 189.2), P¼0.007).
Representative images demonstrating VLU healing from base-
line to week 12 in participants treated with ACT1 and
participants receiving SOC-alone are presented in
Supplementary Figure S1 online.
The categorical analysis of incidence of 100 and 50% ulcer
closure at week 12 was conducted, where participants with
100 and 50% ulcer closure were considered responders. The
combined incidence of 100% ulcer closure at week 12 for all
study centers was significantly greater in the ACT1 treatment
group (57% (ITT) and 74% (PP)), as compared with partici-
pants in the SOC-alone group (28% (ITT) and 30% (PP); ITT:
P¼0.006; PP: Po0.001, w2 analyses), indicating that standard
treatment protocols that incorporated ACT1 had a higher
incidence of 100% reepithelialization. Although the percen-
tage of responders in the ACT1-treated group (63%) reaching
50% closure just failed to reach significance (P¼0.060) over
those receiving SOC-alone (43%), for those participants
adherent to protocol without missing data points (PP popula-
tion) the incidence of ulcers exhibiting 50% closure in ACT1-
treated participants significantly exceeded those in SOC-alone
(80 vs. 51%; P¼ 0.013; Table 2).
Participants in both the ITT and PP populations showed that
ACT1 incorporation in SOC protocols was associated with a
shorter time to 100% ulcer closure during the 12 weeks of
efficacy assessments (ITT: P¼0.041; PP: P¼ 0.008, Cox
hazard ratio), and participants who received ACT1 were
approximately three times more likely to obtain 100% ulcer
closure than were participants not receiving ACT1 (ITT, 2.3;
PP, 3.2; Table 2 and Figure 2). ACT1 treatment was also
associated with a significantly reduced time-to-completion of
50% ulcer closure (ITT: P¼ 0.014; PP: P¼0.006), and
participants in the treatment group had B2.5 times higher
likelihood of reaching 50% closure than did participants in the
SOC control group (ITT: 2.3; PP: 2.6). Ulcer duration, base-
line-ulcer depth, and body mass index were not significant
factors affecting ulcer closure.
There was no statistically significant difference in the
number of responders center-wise between ACT1-treated
populations and SOC-alone populations (ITT: P¼ 0.238; PP:
P¼0.516, Cochran–Mantel–Haenszel analysis with Breslow–
Day).
Recurrence, pain evaluation, and safety analyses
Recurrence, pain, and safety analyses were performed on all
participants with a baseline visit. Over the duration of the
entire study (through follow-up phase), ulcer recurrence was
reported in 10 participants (5 in each treatment group; 11%
total). Of these participants, recurrence occurred during the
follow-up phase after completion of the treatment phase in
two participants in each group (4% total). There was no
statistically significant difference in ulcer recurrence during or
after the study period between treatment and control groups
(PX1.00).
Self-assessment of pain was recorded on a visual analog
scale of 1–10 (1¼ ‘‘no pain’’ and 10¼ ‘‘extreme pain’’) from
baseline to the end of study, including during follow-up visits.
There was no statistical difference in mean intensity of pain
Table 1. Baseline characteristics of participants
ACT1þ SOC
(n¼ 46)
SOC
(n¼46)
Overall
(n¼92)
Clinical characteristics
Age (years)
Mean (SD) 48.2 (12.5) 51.5 (12.9) 49.8 (12.7)
95% Confidence
interval
(44.451.9) (47.7 55.3) (47.2 52.4)
Sex
Male 44 (96%) 39 (85%) 83 (90%)
Female 2 (4%) 7 (15%) 9 (10%)
Race
Indian 46 (100%) 46 (100%) 92 (100%)
Weight (kg)
Mean (SD) 72.2 (15.0) 68.8 (14.7) 70.5 (14.9)
95% Confidence
interval
(67.776.6) (64.4 73.2) (67.4 73.6)
BMI
Mean (SD) 25.1 (4.8) 24.5 (4.4) 24.8 (4.6)
95% Confidence
interval
(23.726.5) (23.5 25.8) (23.9 25.7)
Clinical history
Baseline-ulcer area (cm2)
Mean (SD) 3.5 (3.7) 3.6 (3.7) 3.5 (3.7)
95% Confidence
interval
(2.34.6) (2.5 4.7) (2.7 4.3)
Ulcer location, n
Anteromedial 0 (0%) 1 (2%) 1 (1%)
Anterior side of leg 11 (24%) 9 (20%) 20 (22%)
Lateral malleolus 2 (4%) 6 (13%) 8 (9%)
Lateral side of leg 12 (26%) 8 (17%) 20 (22%)
Medial malleolus 3 (7%) 5 (11%) 8 (9%)
Medial side of leg 17 (37%) 13 (28%) 30 (33%)
Posterior side of leg 1 (2%) 4 (9%) 5 (5%)
Ulcer duration (weeks)
Mean (SD) 62.7 (119.5) 74.0 (175.9) 68.4 (149.7)
95% Confidence
interval
(27.298.2) (21.8126.3) (37.4 99.3)
Ankle Brachial Pressure Index
Mean (SD) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1)
Range (min:max) (0.9:1.4) (0.7:1.4) (0.7:1.4)
Abbreviations: BMI, body mass index; SOC, standard of care.
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from baseline to week 12 between the two treatment groups
for the ITT (ACT1: 0.46 (SD 1.07); SOC-alone: 0.34 (SD 0.71);
P¼0.839) and PP (ACT1: 0.18 (SD 0.39); SOC-alone: 0.48
(SD 0.80); P¼0.119) populations.
Overall, 28 (30.4%) of the 92 participants reported 40
adverse events (AEs; ACT1: 24 events; SOC-alone: 16 events)
that were classified from mild to moderate, including
instances of infection, pain, and wound complications
(described by inflammation, ulcer irritation, and minor
changes in ulcer size). AEs did not segregate in terms of type
or number by the study group, and there were no statistically
significant differences between the two groups in terms of
complications, conditions, or disorders (PX1.00; Table 3). The
number of participants reporting at least one AE was equal (14
participants per group) for both treatment and SOC-alone
groups. Of the 40 events, 35 (87%) recovered and 1 (2%)
event recovered with sequelae. Wound complications for the
ACT1 treatment group were mild to moderate and were
treatment unrelated. Two (2%) serious AEs, death by myocar-
dial infarction and deep vein thrombosis, were reported in the
SOC control group. With the exception of one participant who
died prior to study completion, none of the participants
withdrew from the study because of an AE. No AEs were
judged related to the study medication. Immunologic testing
for peptide is a crucial aspect in determining the safety profile
of ACT1. Anti-ACT1 peptide antibodies were not detected in
the serum from any participant at screening or at the end of
the study at week 12.
DISCUSSION
The results of this clinical efficacy study show that application
of the Cx43 peptide mimetic, ACT1, is safe and effective in
promoting the healing of chronic VLUs and validate the
clinical potential of wound-healing therapeutics that target
connexin-mediated pathways. ACT1 incorporation into con-
ventional VLU treatment protocols involving the maintenance
of a moist wound environment and the application of
compression therapy was associated with a significantly
greater mean percent ulcer closure, median time-to-healing,
and proportion of healing than were VLUs treated with
standard treatment protocols alone.
The reported increased incidence of 100% ulcer closure at
week 12 in ACT1-treated participants (improvements of 28%
(ITT) and 44% (PP) over SOC-alone control) is among the
highest rates of clinical response reported in VLU trials
(Kirsner et al., 2012; Greer et al., 2013; Harding et al.,
2013). An average ulcer size of 3.5 cm2 lasting about 17
months, as described in our study population at the outset of
study, describes wounds that are significantly larger and
persistent than those incorporated in studies that describe
Table 2. Effect of ACT1 on ulcer area and ulcer closure from baseline
ACT1þ SOC
(n¼46),
SOC
(n¼46),
ACT1þ SOC
(n¼35),
SOC
(n¼ 33),
intent-to-treat intent-to-treat per protocol per protocol
Mean % area reduction þ difference at week 12
Mean percent wound closure 1 m (SD) 79.3 (50.4) 36.3 (179.8) 79.0 (51.1) 28.6 (189.2)
% Difference between treatment groups 43% — 50% —
P-value 0.02 — 0.01 —
Incidence of 100% ulcer closure at week 12
Number 26 (57%) 13 (28%) 26 (74%) 10 (30%)
P-value 0.01 — o0.001 —
Incidence of 50% ulcer closure at week 12
Number 29 (63%) 20 (43%) 28 (80%) 17 (52%)
P-value 0.06 — 0.01
Kaplan–Meier weeks to 100% ulcer closure
Median weeks (90% confidence interval) 6.0 (4.08.0) 12.1 (10.1NA) 6.0 (4.0 7.0) NA (12.0–NA)
P-value o0.001 — o0.001 —
Kaplan–Meier weeks to 50% ulcer closure
Median weeks (90% confidence interval) 2.9 (2.13.0) 6.9 (5.0 9.1) 2.9 (2.0 3.0) 8.0 (5.19.9)
P-value o0.001 — o0.001 —
Cox HR for 100% ulcer closure
HR (95% confidence interval) 2.3 (1.05.0) — 3.2 (1.4 7.3) —
P-value 0.04 — 0.01 —
Abbreviations: HR, hazard ratio; NA, not achieved; SOC, standard of care.
1Number of subjects having non-missing observations: intent-to-treat (n¼ 62); per protocol (n¼ 58).
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appropriate surrogate markers for VLU healing (Gelfand et al.,
2002). On the basis of a model derived from a cohort study of
20,000 patients, ulcers fitting into the category of our study
population would have B52% likelihood of healing by 24
weeks with compression bandage SOC (Margolis et al., 2004).
ACT1 incorporation into SOC protocols significantly
enhanced this estimated prognosis, where VLUs treated with
ACT1 healed completely, with a median time of 6 weeks (ITT,
PP) as compared with 12 weeks (ITT) or not achieved (PP) in
the control SOC group.
Given the critical role that connexin signaling has in cell
and tissue homeostasis and angiogenesis, and, by default, in a
slew of pathological processes (Vinken et al., 2006; Pfenniger
et al., 2011), concern with regard to acute or systemic toxicity
is reasonable. In accordance with preclinical animal efficacy
and toxicology data (Gourdie et al., 2006; Rhett et al., 2008;
Ghatnekar et al., 2009; O’Quinn et al., 2011), ACT1
application was not associated with immunogenicity, nor
with a significantly increased proportion or distribution of
AEs. Furthermore, the AEs reported were treatment unrelated.
Clinically speaking, the absence of AEs is encouraging and
may be linked to the relatively short half-life of the peptide.
Although statistical significance in the incidence of ulcer
closure and limited associated risk demonstrates clinical
relevance, this investigation has a few limitations with regard
to the study sample size and uniformity, the lack of informa-
tion with regard to pre-enrollment treatment protocols (i.e.,
length and type of compression therapy received prior to
enrollment), and the lack of a longer study follow-up period to
evaluate ulcer recurrence and patient compliance. Studies
with larger sample sizes are needed (Greer et al., 2013), and
the reported predictions require confirmation in clinical
testing involving larger cohorts of patients. The male-biased
gender gap is the result of cultural bias that may prove
challenging to overcome and again emphasizes the need for
larger study sizes as well as the need for global trials.
Increasingly stringent enrollment criteria designed to ensure
a refractory ulcer population, including an extended run-in
period to exclude patients for whom carefully monitored
standard care would obviate the need for advanced therapy,
will likely provide further information into the clinical efficacy
of ACT1 in additional clinical trials.
VLU recurrence is of significant concern, and future studies
require recurrence evaluation beyond 6 months. In preclinical
studies, ACT1-treated wounds consistently showed marked
reductions in granulation/scar tissue deposition, increased
number of rete pegs in the healed wound epidermis, and
increases in the tensile properties of the healed skin (measured
by stress and strain measurements) as compared with vehicle
control treatments (Ghatnekar et al., 2009). Although
recurrence data indicated no significant difference between
ACT1 and control-treated VLUs, an increase in tensile stretch
suggests future analyses involving larger sample sizes, and an
extended study duration (to incorporate long-term recurrence
data) may likely reveal treatment durability. Furthermore,
despite evidence that hydroxyethyl cellulose placebos do
not have a significant impact on wound healing (Ghatnekar
et al., 2009; Rodgers et al., 2011; Balingit et al., 2012), future
studies may benefit from the incorporation of additional
vehicle control arms. It is anticipated that study limitations
will be addressed in future clinical trials involving multiple
arms, larger and more gender and ethnically diverse patient
populations, extended run-in periods, and accountability for
the relapsing nature of VLUs.
ACT1 represents a first-in-class drug that targets the con-
nexin signaling pathways involved in wound healing that
contribute to the underlying pathophysiology of chronic VLUs.
Attempts to modulate the signaling pathways involved in the
healing of cutaneous wounds have been evaluated in studies
that exogenously apply polypeptide growth promoters, such as
interleukins, and growth factors, but evidence of clinical
efficacy remains limited. Clinical success has been limited to
a number of randomized, double-blind studies evaluating the
therapeutic application of platelet-derived growth factor-BB
homodimers, where enhanced wound healing in stage III and
IV ulcers has been attributed to an increase in macrophage
recruitment during the early phases of wound healing (Robson
et al., 1992; Mustoe et al., 1994). Global matrix metallo-
proteinase modulators aimed at preventing global matrix
metalloproteinase-mediated destruction of local growth
ITT population (n=92)
ACT1 plus SOC
SOC
1
0.8
0.6
0.4
0.2
0 P-value for log-rank test = 0.0006
Pr
ob
ab
ilit
y 
of
 u
lce
r n
ot
 c
lo
sin
g
Weeks
0 2.5 5 7.5 10 12.5
PP population (n=68)
1
0.8
0.6
0.4
0.2
0
Weeks
0 2.5 5 7.5 10 12.5
Pr
ob
ab
ilit
y 
of
 u
lce
r n
ot
 c
lo
sin
g
ACT1 plus SOC
SOC
P-value for log-rank test = < 0.0001
Figure 2. Kaplan–Meier plot of time to 100% ulcer closure with ACT1 and
standard of care (SOC) compared with standard of care alone. (a) Intent-to-
treat (ITT) population. (b) Per protocol (PP) population.
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factors report clinical success when incorporated into wound
dressings (Meaume et al., 2012). To our knowledge, the
present study is the first peer-reviewed, published report of a
clinical trial describing connexins (i.e., Cx43) as biological
targets for wound healing.
Chronic VLUs remain stalled in the initial inflammatory
phase of wound healing and fail to heal with standard SOC
protocols (Eberhardt and Raffetto, 2005; Charles et al., 2008;
O’Meara et al., 2009). Anti-inflammatory flavonoid medi-
cations have shown clinical efficacy in the treatment of
VLUs, putatively via protection from hypoxic damage and
free radicals, and affecting the expression of granulocyte
adhesion molecules (Scallon et al., 2013). In preclinical
animal studies, ACT1 shortened and reduced the amplitude
of the initial inflammatory phase of wound healing, reduced
neutrophil infiltration, reduced wound gape and edema,
and accelerated the rate of wound closure (Ghatnekar
et al., 2009). Molecular studies have determined that
ACT1 selectively inhibits interaction between Cx43 and
the PDZ-2 domain of ZO-1, independent of Cx43
expression, resulting in the release of Cx43 hemichannels
in the cell membrane from the perinexus, where they are
then sequestered into GJ aggregates (Rhett et al., 2011; Rhett
and Gourdie, 2012). Hemichannels provide a paracrine
route for intercellular communication and regulate wound-
healing processes associated with inflammation, edema, and
fibrosis. Reduction of Cx43 hemichannel activity tempers
inflammatory responses, shortens the inflammatory phase,
and enables the tissue injury process to shift toward a
healthy regenerative healing process (Hunter et al., 2005;
Gourdie et al., 2006; Rhett et al., 2008; Ghatnekar et al.,
2009; Rhett et al., 2011; Mendoza-Naranjo et al., 2012).
This mechanism of action in association with studies
that identify abnormal upregulation of Cx43 in VLUs
supports a molecular role for ACT1 in enhancing the
healing rate of chronic VLUs. Further evidence is relayed
in studies where targeting Cx43 with polynucleotide
antisense DNA indicates wound-healing potential via the
acceleration of fibroblast migration and proliferation
(Mendoza-Naranjo et al., 2012).
Recent studies summarizing 20 trials involving 9 advanced
therapies for VLUs report potential in the application of
Apligraf and keratinocyte products in terms of reducing time
to ulcer healing, but also highlight the need for additional
clinical evidence supporting enhanced healing rates and
research involving cost-effective analyses (Greer et al.,
2013). Apligraf, in particular, has been associated with
concerns of cost, shelf-life, and the possibility of disease
transmission (Kim et al., 2007). The significantly enhanced
healing rates and incidence of ulcer closure observed in
ACT1-treated chronic VLUs have global significance
and could translate into significant pharmacoeconomic
Table 3. Summary of adverse events by MedDRA system organ class and preferred safety population (n¼ 92)
ACT1þ SOC (n¼ 46) SOC (n¼ 46) Overall (n¼92) P-value1
Subjects with at least 1 AE 14 (30%2) 14 (30%) 28 (30%) X1.00
Subjects reporting 1 AE 8 (17%) 12 (26%) 20 (22%) 0.31
Subjects reporting 41 AE 6 (13%) 2 (4%) 8 (9%) 0.27
Adverse events n No. of AEs n No. of AEs n No. of AEs
Serious adverse events
Lethal myocardial infarction 0 (0%) 0 1 (2%) 1 1 (1%) 1 —
Deep vein thrombosis 0 (0%) 0 1 (2%) 1 1 (1%) 1 —
Other adverse events
Pyrexia 0 (0%) 0 2 (4%) 2 2 (2%) 2 —
Wound infection 2 (4%) 2 1 (2%) 2 3 (3%) 4 X1.00
Wound complication 7 (15%) 11 5 (11%) 5 12 (13%) 16 0.54
Blister 1 (2%) 1 0 (0%) 0 1 (1%) 1 —
Cough 1 (2%) 1 0 (0%) 0 1 (1%) 1 —
Pneumonitis 1 (2%) 1 0 (0%) 0 1 (1%) 1 —
Venous ulcer pain 6 (13%) 6 4 (9%) 4 10 (11%) 10 0.74
Dermatitis allergic 1 (2%) 1 0 (0%) 0 1 (1%) 1 —
Pruritus 1 (2%) 1 0 (0%) 0 1 (1%) 1 —
Bleeding varicose vein 0 (0%) 0 1 (2%) 1 1 (1%) 1 —
Total AEs in 28 subjects 24 16 40 0.21
Abbreviations: AE, adverse event; SOC, standard of care.
1P-value is calculated by comparing two treatment groups using w2-test.
2Percentage is calculated by taking respective column header group count as denominator.
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benefits by substantially decreasing VLU-related health
care costs and improving patient quality-of-life. Further
investigation of ACT1 in additional, pivotal clinical studies
that directly compare ACT1 with alternative advanced
therapies is warranted.
MATERIALS AND METHODS
Design overview
A randomized, prospective, observer-blinded, parallel group, multi-
center trial targeting patients with a stage II or III VLU, as defined by
the International Association of Enterostomal Therapists, was con-
ducted (Clinical Trials Registry India: CTRI/2011/09/001985). The
study was designed to assess the clinical efficacy and safety of ACT1
in accelerating the healing of chronic VLUs in participants whose
ulcers had remained unresponsive to SOC protocols for at least 4
weeks. The study was designed, conducted, recorded, and reported in
compliance with the International Conference on Harmonisation
Guidelines, the principles of the Declaration of Helsinki, and with
approval from the office of the Drug Controller General of India and
Independent Ethics Committees/Institutional Review Boards. Partici-
pants were informed by site investigators of the risks and benefits and
the option to withdraw from the study at any time, and they signed
informed consent forms before enrollment. Participants were ran-
domly assigned (1:1) to treatment protocols with ACT1 or without
ACT1 and were treated until ulcer closure or up to 14 topical ACT1
applications. Total study duration was 12 months and involved
individual patient enrollment for 6 months, incorporating a total of
18 evaluation visits.
Study procedure
Study procedures were divided into three phases: screening
phase (day:  7 through day 0), treatment phase (day 0 through
week 12), and follow-up phase (month 4 through month 6).
Safety and efficacy were evaluated weekly through the treatment
phase and then monthly through the follow-up phase. During
visit 1 (day  7), ulcers were debrided, without undermining, to
remove fibrin slough or necrotic tissue. Screening procedures
incorporated documentation of medical history, a physical examina-
tion including neurovascular examination, vitals, and electro-
cardiogram, laboratory blood tests for hematology, serum chemistry
and immunologic testing, evaluation of adherence to inclusion
and exclusion criteria, and ulcer evaluation. Participants remained
in the treatment phase until 100% ulcer reepithelialization or
for 12 weeks, whichever occurred first. At each visit during the
treatment phase, ulcers in both groups were cleaned, irrigated,
photographed, traced, assessed for closure, and dressed, and the
self-assessment of pain and AEs were recorded. For each participant
designated in the treatment group, during SOC protocols ACT1
(100mM) was applied topically to the ulcer on day 0 (baseline visit)
and day 3 and then weekly from week 1 to week 12. The ACT1
treatment regimen was designed on the basis of alignment with
currently used SOC protocols and preclinical studies revealing ACT1
mechanism of action (Hunter et al., 2005; Gourdie et al., 2006;
Ghatnekar et al., 2009; Rhett et al., 2011). Participants whose target
ulcer healed completely entered the follow-up phase, during which
AEs and ulcer status/recurrence were assessed. Safety variables
included incidence of treatment-related AEs and the determination
of ACT1 immunogenicity.
Setting and participants
Male or female patients, 18 years or older, with existing VLUs were
recruited and screened by the site investigators at 10 academic
centers located in South Asia. Inclusion criteria (Supplementary
Table S1 online) included having a Stage II or III surface ulcer (as
defined by the International Association of Enterostomal Therapists)
measuring between 0.5 and 40 cm2 post debridement that was
present at least 4 weeks prior to initial screening (i.e., chronic).
Stage II ulcers are defined by partial-thickness skin loss involving
the epidermis, dermis, or both. Stage III ulcers are characterized by
full-thickness skin loss involving damage or necrosis of subcuta-
neous tissue that may extend down to, but not through, underlying
fascia. Ulcers were clinically determined to be of venous origin by
the positive venous reflux test (venous refilling o20 seconds) using
Doppler ultrasound. Participants were excluded if there was a
change in ulcer size by 430% during a 7-day screening period, the
patient was unable to tolerate or comply with compression therapy,
showed signs of ulcer infection, had an Ankle Brachial Pressure
Index o0.65, or the ulcer was heavily exudative (requiring daily
dressing changes). In the presence of multiple ulcers, the largest
ulcer was considered as the target ulcer and assessed in treatment
protocols.
Randomization and interventions
Baseline assessments (Table 1) were completed on patients
who met the initial inclusion/exclusion criteria (Supplementary
Table S1 online) and were registered by the site investigator to
receive treatment assignment. A central block randomization (size 2)
list was prepared by an independent statistician using a validated
computer program (Statistical Analysis Software (SAS v9.1.3 (SAS
Institute, Cary, NC)). Using the Interactive Web Response System,
participants were randomized 1:1 to receive either 100mM ACT1
topical formulation plus SOC or SOC therapy alone. Baseline ulcer
sizes and ulcer duration are well-established markers for predicting
the likelihood of healing (Margolis et al., 2004). To avoid bias due to
these effects, ulcers were further stratified by size (o10 cm2 and
410 cm2). An unblinded coordinator designated by the site
investigator received treatment assignments through the Interactive
Web Response System. The trial sponsor, trial monitors, statisticians,
investigators, and the observer who performed area closure
measurements of ulcer photographs were blinded to treatment
assignments.
The intervention (ACT1 gel formulation) is manufactured as a clear
topical gel formulation (1.25% hydroxyethyl cellulose, manufactured
by Dow Pharmaceutical Sciences, Petaluma, CA) containing ACT1
(100mM) and was spread evenly over the ulcer surface. Preclinical
studies have validated the efficacy and safety of a 100mM concentra-
tion of ACT1 (Ghatnekar et al., 2009). ACT1 dosing strategies were
further optimized in a Phase 1, double-blind, single center, controlled
clinical study designed to evaluate the safety profile and tolerability of
20, 50, 100, and 200mM concentrations of ACT1 versus a
hydroxyethyl cellulose gel vehicle control in 48 healthy participants
following punch biopsy. This study recapitulated previous preclinical
studies that indicated optimal safety (no AEs related to study
medication) and therapeutic efficacy (in terms of accelerating
wound closure) at 100mM ACT1 concentration and laid precedence
for the 100mM ACT1 formulation applied in the current Phase 2 trial.
The hydroxyethyl cellulose formulation was designed to optimize
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ACT1 stability and ulcer application. Hydroxyethyl cellulose placebos
did not have a significant impact on wound healing, an observation
that is supported by recent reports (Ghatnekar et al., 2009; Rodgers
et al., 2011; Balingit et al., 2012).
ACT1 treatment was administered by trial-site–specific research-
trained nurses not acting as investigators. For each participant
designated in the treatment group, during SOC protocols ACT1
(100mM formulation) was applied topically to the ulcer on day 0
(baseline visit) and day 3 and then weekly from week 1 to week 12.
No modifications to ACT1 formulation or application protocol were
made during the course of the study. Ulcers were cared for and
dressed in an identical manner in both groups. SOC procedures were
maintained throughout all trial phases and included thorough irriga-
tion with sterile saline, bleeding control, and application of a saline-
soaked moist nonadherent dressing, which extended 1.27 cm beyond
the ulcer perimeter and inflamed skin margins, followed by a non-
occlusive dressing (fine mesh gauze), either folded or rolled as a
bolster, and the application of a Elastocrep 3M four-layer compres-
sion bandage from the metatarsals up to the tibial plateau to ensure
efficient therapeutic compression to the ulcer site. All bandages were
applied by experienced research nurses using a spiral technique.
Maintaining wound moisture is a critical component of VLU healing
and was a priority in both treatment protocols.
Outcomes and follow-up
Enrolled participants were considered completed for statistical ana-
lysis of efficacy end points at 12 weeks. End point analyses and study
duration were chosen for practical clinical relevance and prognostic
utility and were based on implemented protocols/results from
pertinent published clinical studies (Veves et al., 2001; Kirsner
et al., 2012; O’Meara et al., 2012; Harding et al., 2013). The
primary efficacy end point was mean percent ulcer closure
(reepithelialization) from baseline to week 12. Evaluation of ulcer
closure was performed by the clinically qualified site investigators
and independently evaluated by a central evaluator blinded to the
treatment through computerized planimetry of digital photographs of
the ulcers using public domain software ImageJ (U.S. National
Institutes of Health, Bethesda, MD).
Secondary efficacy end points included time to 50 and 100%
reepithelialization. Self-assessment of pain as measured on a visual
analog scale was also completed at all visits. Incidence of 50% and
complete closure at week 12 were incorporated as exploratory end
points. The inclusion of incidence of 100% ulcer closure by the end
of study in secondary end point analyses is considered as a primary
end point for marketing approval by regulatory authorities (Guidance
for Industry: Chronic Cutaneous Ulcer and Burn Wounds-Developing
Products for Treatment, 2006).
Safety was determined by vitals, laboratory testing, and AE
reporting. Laboratory and immunogenicity tests obtained at baseline
served as a reference and were compared with tests taken during the
study, at study completion, and during follow-up procedures. Labora-
tory evaluations included those required as per the standard for VLU
patient monitoring, including hematology (hemoglobin, hematocrit,
RBC, WBC, and platelets) and blood chemistry (HbA1c, creatinine,
uric acid, blood urea nitrogen, potassium, sodium, chloride, bicarbo-
nate, albumin, aspartate transaminase, alanine transaminase, total
cholesterol). In accordance with good clinical practice, the investi-
gator was permitted to obtain laboratory tests as needed to assess any
AE. Immunologic testing for ACT1 peptide was performed at baseline
and at week 12 using a validated ELISA for the detection of anti-ACT1
antibodies (WuXi Apptec, Philadelphia, PA).
Statistical analysis
The sample size enrolled (n¼ 92), with 40 patients needed per
treatment group, was calculated with reference to the primary end
point (comparing the reduction in wound size as measured by the
mean percentage decrease from baseline to week 12), assuming a
25% difference in favor of participants treated with ACT1. Calcula-
tions were based on using a conservative healing rate of 20% for
control and 45% for ACT1 at a power of 80%, a significance of 95%
(two-sided), a SD of 40%, and adjusted for a 15% dropout rate. At
least 72 total evaluable participants at week 12 were anticipated for a
primary efficacy analysis.
Statistical tests were carried out as two-sided on a 5% level of
significance. Primary and secondary ulcer closure end points were
analyzed using the analysis of covariance Mixed-Model with
Repeated Measure at 95% confidence interval. As a response
variable, mean percent ulcer area reduction from baseline to week
12 was adjusted for strata, ulcer duration, viable tissue (granulation),
exudate level, ankle circumference, and body mass index as covari-
ates, with treatment group, treatment visit, and visit as factors. Clinical
assessment of variables not associated with a defined measurable
outcome was carried out on a scale of 1–5 (1¼ ‘‘much worse’’; 2¼
‘‘worse’’; 3¼ ‘‘same’’; 4¼ ‘‘improved’’; 5¼ ‘‘much improved’’). The
Wilcoxon Mann–Whitney U-test was used for data in which the
normality assumption was tested by Shapiro–Wilk and Q–Q plots. For
time-to-event end points (100 and 50% ulcer closure), the distribution
was estimated by the Kaplan–Meier method, compared by the log-
rank test for statistical significance, and median time (i.e., ulcer
closure for 50% of enrolled participants) was calculated using a 90%
confidence interval to avoid missing the upper limit, in the event that
50% of the participants did not achieve complete ulcer closure by
week 12. Individual and joint effects of covariates on time to 100%
ulcer closure were evaluated using Cox Proportional Hazard.
The exploratory end points (i.e., incidence of 50 and 100% ulcer
closure at week 12) were analyzed overall and by center, assessed by
Fisher’s Exact test (two-tailed), and followed by the Cochran–Mantel–
Haenszel test after adjusting for pooled-center. The Breslow-Day test
was used in conjunction with the Cochran–Mantel–Haenszel test to
determine statistical significance of treatment by pooled-center
interaction. Participant self-assessment of intensity of pain at all
visit time points starting at visit 0 was analyzed by the Wilcoxon
Mann–Whitney U-test.
Sensitivity analysis was performed to establish whether the con-
clusions drawn from the primary analysis were robust. Primary
analysis was perfomed using Proc Mixed in SAS in which missing
values were accounted for using the analysis of covariance method
with repeated measures and the Last Observation-Carried-Forward
approach was used for performing sensitivity analysis. If the ulcer
healed and all further visits were missed, 100% reduction was carried
forward to missing visits until any recurrence.
The site investigators were responsible for ensuring that all AEs,
defined in accordance with ICH E6:1.2, observed or reported, were
properly recorded using precise medical terminology. AEs were
tabulated as per Medical Dictionary for Regulatory Activities v15.1,
indicating number and percentage of participants and number of AEs.
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AEs were evaluated in relation to study drug, seriousness, severity,
action taken, and outcome. Analyses were performed by an inde-
pendent statistician using SAS v9.1.3.
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